Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsSolid TumorsProtocol groupAggressive LymphomasNeuro-OncologyTransplantationDiseaseNHL, B-cell type, primary Lymphoma of the central nervous system SubgroupICD10C83.3MeSHCentral Nervous System NeoplasmsSequenceFreiburg CNS-NHL StudyMATRIXChemotherapyChemo-substanceCarmustineRituximabThiotepaChemo-substanceCarmustineRituximabThiotepaChemo-substanceCarmustineRituximabThiotepaChemo-substanceCarmustineRituximabThiotepaNo. Substances23 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronLevofloxacinParacetamolPrednisoloneValaciclovirSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronLevofloxacinParacetamolPrednisoloneValaciclovirSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronLevofloxacinParacetamolPrednisoloneValaciclovirSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronLevofloxacinParacetamolPrednisoloneValaciclovirNo. Substances79Protocol classificationTherapy classificationcurrent standardIntensityhigh doseTherapy indicationFirst lineTherapy phaseautologous stem cell transplantationTherapy intentioncurativeRisksAnemia Hb below 8g/dlCardiotoxicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaIncrease AminotransferasesInfectionsLeukopeniaMucositisNeutropeniaPyrexiaThrombocytopenia below 50 000/µl only studiesPublicationAuthorIllerhaus GDiseaseErstdiagnose eines primären NHL des ZNS, 18-65 Jahreprimäres ZNS-NHL, ErstdiagnoseOriginAlbert-Ludwigs University, Freiburg, Germany, Freiburger ZNS-NHL ProtokollMATRix / IELSG43 StudieProtocols in Revision 2 protocols foundMATRIX - Carmustine 400 / Thiotepa 5, primary Lymphoma of the central nervous system, Stem Cell Transplantation, Autologous, MA (PID890 V2.2)Rituximab 375 / Carmustine 400 / Thiotepa 5, primary central nervous system Lymphoma, conditioning, cycle 5 (PID1883 V1.0)
